Monday, 19 October 2026European Markets

AFFLUENT MEDICAL Stock Went Up By Over 10% At Session Start Today

Loading stream...

(vianews) - shares of affluent medical (cac 40: afme.pa) rose by a staggering 10.68% to €1.66 at 10:42 est on thursday, following the last session's upward trend. cac 40 is jumping 0.45% to €7,332.22, after four sequential sessions in a row of losses. this seems, up until now, a somewhat up trend exchanging session today.

affluent medical's last close was €1.47, 70.28% below its 52-week high of €4.94.

about affluent medical

affluent medical sa develops minimally invasive medical devices for the treatment of heart and vascular diseases in france. it develops kardiozis technology for the treatment of abdominal aortic aneurysm; kalios and epygon implants to treat mitral insufficiency; and artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. the company was founded in 2011 and is based in aix-en-provence, france.

earnings per share

as for profitability, affluent medical has a trailing twelve months eps of €-0.987.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -35.51%.

more news about affluent medical (afme.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Sovereign, Local and Open AI: Infrastructure and Applied Intelligence Scale Up While Frontier-Lab Safety Scrutiny Grows
AI is shifting from cloud-rented models toward locally run, owned and open intelligence. ASUS/NVIDIA RTX Spark laptops pair with Nous Research's Hermes and ComfyUI, and Microsoft pushes hybrid local/cloud Windows. Cisco, NVIDIA and Marvell build open high-bandwidth AI infrastructure, and Hesai supplies real-world data for physical AI. In finance and commerce, Intuit, Zeta, Parloa/TELUS Digital and Snipp embed agentic AI into trusted financial and customer workflows, while OpenAI's math breakthroughs, its security disclosures and an executive's departure from its safety role keep safety and governance scrutiny high.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,397 source documents archived
Query this data → isubstrate.com